|
US4601704A
(en)
|
1983-10-27 |
1986-07-22 |
Abbott Laboratories |
Container mixing system with externally mounted drug container
|
|
US5322691A
(en)
|
1986-10-02 |
1994-06-21 |
Sohrab Darougar |
Ocular insert with anchoring protrusions
|
|
US4914210A
(en)
|
1987-10-02 |
1990-04-03 |
Cetus Corporation |
Oligonucleotide functionalizing reagents
|
|
US5194596A
(en)
|
1989-07-27 |
1993-03-16 |
California Biotechnology Inc. |
Production of vascular endothelial cell growth factor
|
|
US6005087A
(en)
|
1995-06-06 |
1999-12-21 |
Isis Pharmaceuticals, Inc. |
2'-modified oligonucleotides
|
|
US5668264A
(en)
|
1990-06-11 |
1997-09-16 |
Nexstar Pharmaceuticals, Inc. |
High affinity PDGF nucleic acid ligands
|
|
US5731424A
(en)
|
1990-06-11 |
1998-03-24 |
Nexstar Pharmaceuticals, Inc. |
High affinity TGFβ nucleic acid ligands and inhibitors
|
|
US5683867A
(en)
|
1990-06-11 |
1997-11-04 |
Nexstar Pharmaceuticals, Inc. |
Systematic evolution of ligands by exponential enrichment: blended SELEX
|
|
US5459015A
(en)
|
1990-06-11 |
1995-10-17 |
Nexstar Pharmaceuticals, Inc. |
High-affinity RNA ligands of basic fibroblast growth factor
|
|
US5846713A
(en)
|
1990-06-11 |
1998-12-08 |
Nexstar Pharmaceuticals, Inc. |
High affinity HKGF nucleic acid ligands and inhibitors
|
|
US5837834A
(en)
|
1990-06-11 |
1998-11-17 |
Nexstar Pharmaceuticals, Inc. |
High affinity HKGF nucleic acid ligands and inhibitors
|
|
US5660985A
(en)
|
1990-06-11 |
1997-08-26 |
Nexstar Pharmaceuticals, Inc. |
High affinity nucleic acid ligands containing modified nucleotides
|
|
US5731144A
(en)
|
1990-06-11 |
1998-03-24 |
Nexstar Pharmaceuticals, Inc. |
High affinity TGFβ nucleic acid ligands
|
|
US6465188B1
(en)
|
1990-06-11 |
2002-10-15 |
Gilead Sciences, Inc. |
Nucleic acid ligand complexes
|
|
US5496938A
(en)
|
1990-06-11 |
1996-03-05 |
Nexstar Pharmaceuticals, Inc. |
Nucleic acid ligands to HIV-RT and HIV-1 rev
|
|
US6147204A
(en)
|
1990-06-11 |
2000-11-14 |
Nexstar Pharmaceuticals, Inc. |
Nucleic acid ligand complexes
|
|
US6168778B1
(en)
|
1990-06-11 |
2001-01-02 |
Nexstar Pharmaceuticals, Inc. |
Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
|
|
US5270163A
(en)
|
1990-06-11 |
1993-12-14 |
University Research Corporation |
Methods for identifying nucleic acid ligands
|
|
US5811533A
(en)
|
1990-06-11 |
1998-09-22 |
Nexstar Pharmaceuticals, Inc. |
High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
|
|
CA2084987C
(en)
|
1990-06-11 |
2007-02-13 |
Gilead Sciences, Inc. |
Nucleic acid ligands
|
|
US6011020A
(en)
|
1990-06-11 |
2000-01-04 |
Nexstar Pharmaceuticals, Inc. |
Nucleic acid ligand complexes
|
|
US6395888B1
(en)
|
1996-02-01 |
2002-05-28 |
Gilead Sciences, Inc. |
High affinity nucleic acid ligands of complement system proteins
|
|
US5674685A
(en)
|
1990-06-11 |
1997-10-07 |
Nexstar Pharmaceuticals, Inc. |
High affinity PDGF nucleic acid ligands
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US5756291A
(en)
|
1992-08-21 |
1998-05-26 |
Gilead Sciences, Inc. |
Aptamers specific for biomolecules and methods of making
|
|
US6410322B1
(en)
|
1993-07-27 |
2002-06-25 |
Hybridon Inc |
Antisense oligonucleotide inhibition of vascular endothelial growth factor expression
|
|
US5731294A
(en)
|
1993-07-27 |
1998-03-24 |
Hybridon, Inc. |
Inhibition of neovasularization using VEGF-specific oligonucleotides
|
|
US5641756A
(en)
|
1993-07-27 |
1997-06-24 |
Hybridon, Inc. |
Modified VEGF oligonucleotides
|
|
US5919455A
(en)
|
1993-10-27 |
1999-07-06 |
Enzon, Inc. |
Non-antigenic branched polymer conjugates
|
|
AU5698094A
(en)
|
1993-12-09 |
1995-06-27 |
Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh |
Antisense nucleic acid for the treatment of diseases in which expression of bfgf, pdgf-a or pdgf-b plays a pathogenic role
|
|
US5700823A
(en)
|
1994-01-07 |
1997-12-23 |
Sugen, Inc. |
Treatment of platelet derived growth factor related disorders such as cancers
|
|
US6448077B1
(en)
|
1994-02-10 |
2002-09-10 |
Imclone Systems, Inc. |
Chimeric and humanized monoclonal antibodies specific to VEGF receptors
|
|
US6403088B1
(en)
|
1995-08-01 |
2002-06-11 |
Helsinki University Licensing, Ltd. |
Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
|
|
US5932462A
(en)
|
1995-01-10 |
1999-08-03 |
Shearwater Polymers, Inc. |
Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
|
|
US5928939A
(en)
|
1995-03-01 |
1999-07-27 |
Ludwig Institute For Cancer Research |
Vascular endothelial growth factor-b and dna coding therefor
|
|
IL117645A
(en)
|
1995-03-30 |
2005-08-31 |
Genentech Inc |
Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
|
|
US5859228A
(en)
|
1995-05-04 |
1999-01-12 |
Nexstar Pharmaceuticals, Inc. |
Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
|
|
US5723594A
(en)
|
1995-06-07 |
1998-03-03 |
Nexstar Pharmaceuticals, Inc. |
High affinity PDGF nucleic acid ligands
|
|
US6207816B1
(en)
|
1995-06-02 |
2001-03-27 |
Nexstar Pharmaceuticals, Inc. |
High affinity oligonucleotide ligands to growth factors
|
|
US6229002B1
(en)
*
|
1995-06-07 |
2001-05-08 |
Nexstar Pharmaceuticlas, Inc. |
Platelet derived growth factor (PDGF) nucleic acid ligand complexes
|
|
US6699843B2
(en)
|
1995-06-07 |
2004-03-02 |
Gilead Sciences, Inc. |
Method for treatment of tumors using nucleic acid ligands to PDGF
|
|
US5730977A
(en)
|
1995-08-21 |
1998-03-24 |
Mitsui Toatsu Chemicals, Inc. |
Anti-VEGF human monoclonal antibody
|
|
ATE242809T1
(de)
|
1995-09-08 |
2003-06-15 |
Genentech Inc |
Vegf-verwandtes protein
|
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
|
IL129497A0
(en)
|
1996-10-25 |
2000-02-29 |
Nexstar Pharmaceuticals Inc |
Vascular endothelial growth factor (vegf) nucleic acid ligand complexes
|
|
US6051698A
(en)
|
1997-06-06 |
2000-04-18 |
Janjic; Nebojsa |
Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
|
|
US6426335B1
(en)
|
1997-10-17 |
2002-07-30 |
Gilead Sciences, Inc. |
Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
|
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
|
US20070059302A1
(en)
|
1997-04-07 |
2007-03-15 |
Genentech, Inc. |
Anti-vegf antibodies
|
|
US20020032315A1
(en)
|
1997-08-06 |
2002-03-14 |
Manuel Baca |
Anti-vegf antibodies
|
|
KR100870353B1
(ko)
|
1997-04-07 |
2008-11-25 |
제넨테크, 인크. |
항-ｖｅｇｆ 항체
|
|
KR100504405B1
(ko)
|
1998-10-22 |
2005-07-29 |
정세영 |
데커신을 포함하는 의약 조성물
|
|
GB9824579D0
(en)
|
1998-11-10 |
1999-01-06 |
Novartis Ag |
Organic compounds
|
|
EP1135498B1
(en)
|
1998-11-18 |
2008-01-23 |
Genentech, Inc. |
Antibody variants with higher binding affinity compared to parent antibodies
|
|
DK1140175T3
(da)
|
1998-12-21 |
2006-08-14 |
Ludwig Inst Cancer Res |
Antistoffer mod trunkeret VEGF-D og anvendelser deraf
|
|
ES2223705T3
(es)
|
1999-04-28 |
2005-03-01 |
Board Of Regents, The University Of Texas System |
Composiciones y metodos para el tratamiento de cancer mediante inhibi cion selectiva del vegf.
|
|
US7087411B2
(en)
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
|
US7306799B2
(en)
|
1999-06-08 |
2007-12-11 |
Regeneron Pharmaceuticals, Inc. |
Use of VEGF inhibitors for treatment of eye disorders
|
|
US7070959B1
(en)
|
1999-06-08 |
2006-07-04 |
Regeneron Pharmaceuticals, Inc. |
Modified chimeric polypeptides with improved pharmacokinetic properties
|
|
US6382219B1
(en)
|
1999-06-08 |
2002-05-07 |
Jeffery A. Jelten |
Tooth flossing device
|
|
US7303746B2
(en)
|
1999-06-08 |
2007-12-04 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating eye disorders with modified chimeric polypeptides
|
|
DE29915878U1
(de)
|
1999-09-09 |
2000-10-26 |
Disetronic Licensing Ag, Burgdorf |
Vorrichtung zur Umfüllung von Arzneimitteln und Kanülenanordnung
|
|
US7078390B1
(en)
|
1999-10-15 |
2006-07-18 |
Gentier Biosystems Incorporation |
Ribozymes to growth factor originating in human platelet
|
|
DE60040876D1
(de)
|
1999-10-21 |
2009-01-02 |
Alcon Inc |
Medikamentenzuführeinrichtung
|
|
TWI310684B
(en)
|
2000-03-27 |
2009-06-11 |
Bristol Myers Squibb Co |
Synergistic pharmaceutical kits for treating cancer
|
|
JP2003528632A
(ja)
|
2000-03-31 |
2003-09-30 |
インスティティ・パスツール |
血管内皮成長因子（ｖｅｇｆ）−媒介性脈管形成を阻害するペプチド、該ペプチドをエンコードするポリヌクレオチド及びその使用方法
|
|
WO2001087351A1
(en)
|
2000-05-17 |
2001-11-22 |
Gilead Sciences, Inc. |
Method for treatment of tumors using nucleic acid ligands to pdgf
|
|
ATE404140T1
(de)
|
2000-08-30 |
2008-08-15 |
Univ Johns Hopkins |
Vorrichtung zur intraokularen wirkstoffverabreichung
|
|
AU2002255284B2
(en)
|
2001-04-27 |
2007-10-04 |
Kyowa Kirin Co., Ltd. |
Quinoline derivative having azolyl group and quinazoline derivative
|
|
US6585691B1
(en)
|
2001-05-11 |
2003-07-01 |
Jonathan J. Vitello |
Tamper evident end cap assembly for a loaded syringe and process
|
|
GB0119249D0
(en)
|
2001-08-07 |
2001-10-03 |
Novartis Ag |
Organic compounds
|
|
US6927293B2
(en)
|
2001-08-30 |
2005-08-09 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
EP1436329A4
(en)
|
2001-09-20 |
2005-04-27 |
Alexion Pharma Inc |
ANTI-PDGF ANTIBODIES AND METHODS FOR PRODUCING FOCUSED ANTIBODIES
|
|
HRP20040406A2
(en)
|
2001-11-09 |
2005-02-28 |
Eyetech Pharmaceuticals |
Methods for treating ocular neovascular diseases
|
|
CA2487809A1
(en)
|
2002-06-18 |
2003-12-24 |
Archemix Corp. |
Aptamer-toxin molecules and methods for using same
|
|
US20040249130A1
(en)
|
2002-06-18 |
2004-12-09 |
Martin Stanton |
Aptamer-toxin molecules and methods for using same
|
|
GB0215844D0
(en)
|
2002-07-09 |
2002-08-14 |
Novartis Ag |
Organic compounds
|
|
US20070184089A1
(en)
|
2002-07-15 |
2007-08-09 |
Alcon, Inc. |
Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use
|
|
US8828373B2
(en)
|
2002-11-20 |
2014-09-09 |
Nof Corporation |
Polyalkylene glycol derivative and modified bio-related substance
|
|
US8003117B2
(en)
|
2002-11-20 |
2011-08-23 |
Nof Corporation |
Polyalkylene glycol derivative and modified bio-related substance
|
|
JP4412461B2
(ja)
|
2002-11-20 |
2010-02-10 |
日油株式会社 |
修飾された生体関連物質、その製造方法および中間体
|
|
US10100316B2
(en)
|
2002-11-21 |
2018-10-16 |
Archemix Llc |
Aptamers comprising CPG motifs
|
|
US20090053138A1
(en)
|
2002-11-21 |
2009-02-26 |
Preiss Jeffrey R |
Stabilized Aptamers to Platelet Derived Growth Factor and their Use as Oncology Therapeutics
|
|
WO2006050498A2
(en)
|
2004-11-02 |
2006-05-11 |
Archemix Corp. |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
US20050124565A1
(en)
|
2002-11-21 |
2005-06-09 |
Diener John L. |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
AU2003294437A1
(en)
|
2002-11-21 |
2004-06-18 |
Archemix Corporation |
Multivalent aptamer therapeutics with improved pharmacodynamic properties and methods of making and using the same
|
|
US20040253243A1
(en)
|
2003-01-21 |
2004-12-16 |
David Epstein |
Aptamer therapeutics useful in ocular pharmacotherapy
|
|
US8039443B2
(en)
|
2002-11-21 |
2011-10-18 |
Archemix Corporation |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
US7459436B2
(en)
|
2002-11-22 |
2008-12-02 |
Hoffmann-La Roche Inc. |
Treatment of disturbances of iron distribution
|
|
US20040197804A1
(en)
|
2002-12-03 |
2004-10-07 |
Keefe Anthony D. |
Method for in vitro selection of 2'-substituted nucleic acids
|
|
US20050048099A1
(en)
|
2003-01-09 |
2005-03-03 |
Allergan, Inc. |
Ocular implant made by a double extrusion process
|
|
AU2004206955A1
(en)
*
|
2003-01-21 |
2004-08-05 |
Archemix Corp. |
Aptamer therapeutics useful in ocular pharmacotherapy
|
|
US20060167435A1
(en)
|
2003-02-18 |
2006-07-27 |
Adamis Anthony P |
Transscleral drug delivery device and related methods
|
|
EP1620547B1
(en)
|
2003-04-21 |
2014-06-18 |
Archemix LLC |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
EP1639001A1
(en)
|
2003-06-27 |
2006-03-29 |
Dnavec Research Inc. |
Method for transplanting lymphohematopoietic cells into mammal
|
|
CL2004001996A1
(es)
|
2003-08-08 |
2005-05-06 |
Eyetech Pharmaceuticals Inc |
Aptameros anti-vegf (factor de crecimiento endotelial vascular) con bloqueo nucleotidico 5'-5' o 3'-3' invertido, composicion que lo contiene, util para trastornos de neovascularizacion.
|
|
AU2004268614C1
(en)
|
2003-08-27 |
2010-10-28 |
Ophthotech Corporation |
Combination therapy for the treatment of ocular neovascular disorders
|
|
US8298532B2
(en)
|
2004-01-16 |
2012-10-30 |
Regeneron Pharmaceuticals, Inc. |
Fusion polypeptides capable of activating receptors
|
|
US7803931B2
(en)
|
2004-02-12 |
2010-09-28 |
Archemix Corp. |
Aptamer therapeutics useful in the treatment of complement-related disorders
|
|
SI1745062T1
(sl)
|
2004-04-22 |
2014-09-30 |
Regado Biosciences, Inc. |
Izobljšani modulatorji koagulacijskih faktrojev
|
|
US8591885B2
(en)
|
2004-04-30 |
2013-11-26 |
Allergan, Inc. |
Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
|
|
US20060182783A1
(en)
|
2004-04-30 |
2006-08-17 |
Allergan, Inc. |
Sustained release intraocular drug delivery systems
|
|
US8529927B2
(en)
|
2004-04-30 |
2013-09-10 |
Allergan, Inc. |
Alpha-2 agonist polymeric drug delivery systems
|
|
US20050244500A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Intravitreal implants in conjuction with photodynamic therapy to improve vision
|
|
US20050244462A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Devices and methods for treating a mammalian eye
|
|
US20050244471A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
|
|
KR100897379B1
(ko)
|
2004-06-08 |
2009-05-14 |
쳉두 캉홍 바이오테크놀로지스 코. 리미티드 |
혈관신생-저해 키메릭 단백질 및 그 사용
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
EP1877438A2
(en)
|
2005-02-02 |
2008-01-16 |
Regeneron Pharmaceuticals, Inc. |
Method of treating eye injury with local administration of a vegf inhibitor
|
|
EP1853298A2
(en)
|
2005-02-11 |
2007-11-14 |
Regeneron Pharmaceuticals, Inc. |
Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
|
|
US20090075342A1
(en)
|
2005-04-26 |
2009-03-19 |
Sharon Cload |
Metabolic profile directed aptamer medicinal chemistry
|
|
US7303041B2
(en)
|
2005-08-22 |
2007-12-04 |
Key Safety Systems, Inc. |
Vehicle soft impact detection
|
|
CA2622573A1
(en)
|
2005-09-16 |
2007-03-29 |
(Osi) Eyetech, Inc. |
Ophthalmic syringe
|
|
US20080076742A1
(en)
|
2005-10-31 |
2008-03-27 |
Wisconsin Alumni Research Foundation |
Methods and compositions for treating diseases associated with neovascualrization
|
|
HUE026423T2
(en)
|
2005-11-04 |
2016-05-30 |
Genentech Inc |
Use of complement biosynthetic pathway inhibitors for treating eye diseases
|
|
CA3009846C
(en)
*
|
2006-03-08 |
2021-08-31 |
David Epstein |
Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders
|
|
CN101443050A
(zh)
*
|
2006-03-08 |
2009-05-27 |
阿切埃米克斯有限公司 |
治疗视觉失调中使用的补体结合适体和抗-c5药物
|
|
US20080152654A1
(en)
|
2006-06-12 |
2008-06-26 |
Exegenics, Inc., D/B/A Opko Health, Inc. |
COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOGENESIS
|
|
EP3753548A1
(en)
|
2006-06-16 |
2020-12-23 |
Regeneron Pharmaceuticals, Inc. |
Vegf antagonist formulations suitable for intravitreal administration
|
|
US7632244B2
(en)
|
2006-08-10 |
2009-12-15 |
Comar, Inc. |
Tamper evident tip cap assembly
|
|
EP2091481A2
(en)
|
2006-12-18 |
2009-08-26 |
Alcon Research, Ltd. |
Devices and methods for ophthalmic drug delivery
|
|
EP2166844A4
(en)
|
2007-06-07 |
2013-09-04 |
Evonik Corp |
DOSAGE FORMS WITH EXTENDED ACTION AND REDUCED MASS
|
|
HUE032894T2
(hu)
|
2008-06-25 |
2017-11-28 |
Esbatech Alcon Biomed Res Unit |
VEGF-gátló, stabilis és oldható antitestek
|
|
EP2358746B1
(en)
|
2008-11-03 |
2020-09-16 |
Molecular Partners AG |
Binding proteins inhibiting the vegf-a receptor interaction
|
|
EP3028707A1
(en)
*
|
2009-05-01 |
2016-06-08 |
Ophthotech Corporation |
Methods for treating or preventing ophthalmological diseases
|
|
TWI510248B
(zh)
*
|
2009-06-17 |
2015-12-01 |
Abbvie Biotherapeutics Inc |
抗－ｖｅｇｆ抗體及其用途
|
|
WO2011137344A2
(en)
|
2010-04-30 |
2011-11-03 |
Lpath, Inc. |
Anti-s1p antibody treatment of patients with ocular disease
|
|
TWI510246B
(zh)
|
2010-04-30 |
2015-12-01 |
Molecular Partners Ag |
抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
|
|
SG187938A1
(en)
|
2010-08-26 |
2013-04-30 |
Abbvie Inc |
Dual variable domain immunoglobulins and uses thereof
|
|
US8353869B2
(en)
|
2010-11-02 |
2013-01-15 |
Baxa Corporation |
Anti-tampering apparatus and method for drug delivery devices
|
|
PE20150159A1
(es)
*
|
2011-12-21 |
2015-02-08 |
Novartis Ag |
Composiciones y metodos para anticuerpos que actuan sobre el factor p
|
|
ES2742284T3
(es)
|
2012-03-28 |
2020-02-13 |
Somalogic Inc |
Aptámeros contra PDGF y VEGF y su utilización en el tratamiento de afecciones mediadas por PDGF y VEGF
|
|
US20130323242A1
(en)
|
2012-06-01 |
2013-12-05 |
Ophthotech Corp. |
Compositions comprising an anti-pdgf aptamer and a vegf antagonist
|
|
AR091237A1
(es)
*
|
2012-06-01 |
2015-01-21 |
Ophthotech Corp |
Composiciones que comprenden un aptamero anti factor de crecimiento derivado de plaquetas (anti-pdgf) y un antagonista de factor de crecimiento de endotelio vascular (vegf)
|
|
JO3405B1
(ar)
|
2013-01-09 |
2019-10-20 |
Regeneron Pharma |
الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
|
|
EA201690212A8
(ru)
*
|
2013-07-12 |
2016-08-31 |
Офтотек Корпорейшн |
Способы лечения или профилактики офтальмологических патологических состояний
|
|
CN106852125A
(zh)
|
2014-08-11 |
2017-06-13 |
奥普索特克公司 |
用于治疗或预防眼科病的方法
|
|
WO2019040397A1
(en)
|
2017-08-21 |
2019-02-28 |
Ophthotech Corporation |
METHOD FOR TREATING OR PREVENTING MACULAR DEGENERATION OF THE NEOVASCULAR AGE
|